{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T19:06:34Z","timestamp":1775243194713,"version":"3.50.1"},"reference-count":37,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1752,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1111\/j.1365-2036.2010.04508.x","type":"journal-article","created":{"date-parts":[[2010,11,15]],"date-time":"2010-11-15T01:41:28Z","timestamp":1289785288000},"page":"213-224","source":"Crossref","is-referenced-by-count":35,"title":["Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5\u2003mg or 10\u2003mg once daily in patients with non-erosive reflux disease"],"prefix":"10.1111","volume":"33","author":[{"given":"Y.","family":"Kinoshita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Ashida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Hongo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"The Japan Rabeprazole Study Group for NERD","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,11,14]]},"reference":[{"key":"10.1111\/j.1365-2036.2010.04508.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/j.1572-0241.2006.00630.x","article-title":"The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus","volume":"101","author":"Vakil","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04508.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1572-0241.2001.03511.x","article-title":"Nonerosive reflux disease - current concepts and dilemmas","volume":"96","author":"Fass","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04508.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/01.mcg.0000225631.07039.6d","article-title":"Erosive Esophagitis and nonerosive reflux disease (NERD) - comparison of epidemiologic, physiologic, and therapeutic characteristics","volume":"41","author":"Fass","year":"2007","journal-title":"J Clin Gastroenterol"},{"issue":"Suppl.","key":"10.1111\/j.1365-2036.2010.04508.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0002-9270(03)00009-1","article-title":"Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease","volume":"98","author":"Fass","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"Suppl. 1","key":"10.1111\/j.1365-2036.2010.04508.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2036.2005.02608.x","article-title":"Review article: quality of life issues in gastro-oesophageal reflux diseases","volume":"22","author":"Quigley","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2010.04508.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1080\/00365520510023260","article-title":"Prevalence of endoscopically negative and positive gastroesophageal reflux disease in the Japanese","volume":"40","author":"Mishima","year":"2005","journal-title":"Scand J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04508.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s00535-007-2022-3","article-title":"Validity of endoscopic classification of nonerosive reflux disease","volume":"42","author":"Joh","year":"2007","journal-title":"J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04508.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/j.1572-0241.2005.40966.x","article-title":"Differences in clinical characteristics between patients with endoscopy-negative reflux disease and erosive esophagitis in Japan","volume":"100","author":"Fujiwara","year":"2005","journal-title":"Am J Gastroenterol"},{"issue":"Suppl. 1","key":"10.1111\/j.1365-2036.2010.04508.x-BIB9|cit9","first-page":"7","article-title":"Non-erosive reflux disease and atypical gastro-oesophageal reflux disease manifestations: treatment results","volume":"66","author":"Galmiche","year":"2006","journal-title":"Drugs"},{"key":"10.1111\/j.1365-2036.2010.04508.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1053\/gast.2001.24840","article-title":"Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole","volume":"120","author":"Vela","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2010.04508.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/gut.2005.074690","article-title":"Determinants of perception of heartburn and regurgitation","volume":"55","author":"Bredenoord","year":"2006","journal-title":"Gut"},{"issue":"Suppl. 1","key":"10.1111\/j.1365-2036.2010.04508.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1365-2036.2004.01990.x","article-title":"Oesophageal hypersensitivity in Japanese patients with non-erosive gastro-oesophageal reflux diseases","volume":"20","author":"Miwa","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl.","key":"10.1111\/j.1365-2036.2010.04508.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/S0002-9270(03)00011-X","article-title":"Diagosis of symptomatic gastroesophageal reflux disease","volume":"98","author":"Kahrilas","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04508.x-BIB14|cit14","first-page":"1901","article-title":"Gastroesophageal reflux disease - should we adopt a new conceptual framework?","volume":"97","author":"Fass","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"Suppl. 2","key":"10.1111\/j.1365-2036.2010.04508.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1136\/gut.44.2008.S1","article-title":"An evidence-based appraisal of reflux disease management - The Genval Workshop Report","volume":"44","author":"Dent","year":"1999","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2010.04508.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1572-0241.2005.41217.x","article-title":"Updated guidelines for the diagnosis and treatment of gastroephageal reflux disease","volume":"100","author":"DeVault","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04508.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1440-1746.2007.05249.x","article-title":"Asia-Pacific consensus on the management of gastroesophageal reflux disease: update","volume":"23","author":"Fock","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2036.2010.04508.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.3748\/wjg.v11.i20.3091","article-title":"Rabeprazole vs esomeprazole in non-erosive gastroesophageal reflux disease: a randomized, double-blind study in urban asia","volume":"11","author":"Fock","year":"2005","journal-title":"World J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04508.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1046\/j.1440-1746.2003.03190.x","article-title":"Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole","volume":"18","author":"Adachi","year":"2003","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2036.2010.04508.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1365-2036.2002.01181.x","article-title":"Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis","volume":"16","author":"Robinson","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2010.04508.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1046\/j.1365-2036.2002.01207.x","article-title":"A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease","volume":"16","author":"Holtmann","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl. 6","key":"10.1111\/j.1365-2036.2010.04508.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1365-2036.2004.02162.x","article-title":"Relief of symptoms in gastric acid-related diseases-correlation with acid suppression in rabeprazole treatment","volume":"20","author":"Miner","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl. 6","key":"10.1111\/j.1365-2036.2010.04508.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2036.2004.02161.x","article-title":"Relationship between the metabolism and efficacy of proton pump inhibitors-focus on rabeprazole","volume":"20","author":"Horn","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2010.04508.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1517\/phgs.5.2.181.27483","article-title":"Pharmacogenomics of proton pump inhibitors","volume":"5","author":"Furuta","year":"2004","journal-title":"Pharmacogenomics"},{"key":"10.1111\/j.1365-2036.2010.04508.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1365-2036.2001.00980.x","article-title":"Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes","volume":"15","author":"Horai","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2010.04508.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/j.1572-0241.2002.05769.x","article-title":"Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial","volume":"97","author":"Miner","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04508.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/gut.41.4.452","article-title":"Helicobacter pylori independent chronological change in gastric acid secretion in the Japanese","volume":"41","author":"Kinoshita","year":"1997","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2010.04508.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1046\/j.1440-1746.2000.02131.x","article-title":"Effect of age and Helicobacter pylori infection on gastric acid secretion","volume":"15","author":"Haruma","year":"2000","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2036.2010.04508.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1053\/gast.1996.v110.pm8612992","article-title":"Effects of aging and gastritis on gastric acid and pepsin secretion in humans: a prospective study","volume":"110","author":"Feldman","year":"1996","journal-title":"Gastroenterology"},{"issue":"Suppl. 231","key":"10.1111\/j.1365-2036.2010.04508.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/003655299750025237","article-title":"Three-month prevalence rates of gastrointestinal symptoms and the influence of demographic factors: results from the domestic\/international gastroenterology surveillance study (DIGEST)","volume":"34","author":"Stanghellini","year":"1999","journal-title":"Scand J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04508.x-BIB31|cit31","first-page":"1459","article-title":"Endoscopic findings of GERD","volume":"62","author":"Hoshihara","year":"2004","journal-title":"Nippon Rinsho"},{"key":"10.1111\/j.1365-2036.2010.04508.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00535-006-1775-4","article-title":"Minimal changes in reflux esophagitis: red ones and white ones","volume":"41","author":"Hongo","year":"2006","journal-title":"J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04508.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1517\/14656566.5.1.137","article-title":"Review of rabeprazole in the treatment of gastro-oesophageal reflux disease","volume":"5","author":"Thjodleifsson","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"10.1111\/j.1365-2036.2010.04508.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1542-3565(04)00288-5","article-title":"Effectiveness of proton pump inhibitors in nonerosive reflux disease","volume":"2","author":"Dean","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2036.2010.04508.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s10620-005-3000-3","article-title":"Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease","volume":"50","author":"Kahrilas","year":"2005","journal-title":"Dig Dis Sci"},{"key":"10.1111\/j.1365-2036.2010.04508.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-2036.2006.02983.x","article-title":"Predictors of treatment response in patients with non-erosive reflux disease","volume":"24","author":"Talley","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2010.04508.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2036.2004.01999.x","article-title":"Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease","volume":"20","author":"Bytzer","year":"2004","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2010.04508.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2036.2010.04508.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T14:37:46Z","timestamp":1636814266000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2010.04508.x"}},"subtitle":["Randomised clinical trial: rabeprazole 5 vs. 10\u2003mg in NERD"],"short-title":[],"issued":{"date-parts":[[2010,11,14]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2010.04508.x","relation":{},"ISSN":["0269-2813"],"issn-type":[{"value":"0269-2813","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11,14]]}}}